Fort Washington Investment Advisors 13F: Cuts JNJ Stake by $143M

Fort Washington Investment Advisors reduced its holdings in Johnson & Johnson (NYSE: JNJ) by 57.2% during the quarter, according to a Form 13F filing submitted to the Securities and Exchange Commission on October 15, 2026. Because 13F filings are backward-looking, the report reflects holdings as of the close of the quarter and may not represent the fund's current position.

Inside Fort Washington Investment Advisors's Johnson & Johnson Trade

The fund sold 539,918 shares during the period, leaving it with 404,591 shares of the healthcare company. The remaining stake had a reported value of $107,111,429 at the time of the filing.

Other Institutional Activity in Johnson & Johnson

Blackrock Inc. trimmed its holdings by 1,280,271 shares, ending with 212,098,264 shares worth about $54,203,831,830. Vanguard Capital Management LLC grew its holdings by 626,400 shares, ending with 157,226,374 shares worth about $40,180,771,755. State Street Corporation added 293,661 shares, bringing its total to 133,776,025 shares valued at about $34,187,800,622. Vanguard Portfolio Management LLC boosted its stake by 857,431 shares to finish with 64,370,816 shares worth approximately $16,450,605,579. Geode Capital Management, LLC reduced its position by 76,912 shares, holding 59,086,417 shares valued at about $15,100,124,584.

Johnson & Johnson Stock Up 0.5%

Johnson & Johnson recently traded around $255.22, sitting 3.8% below its 50-day moving average of $265.26 and 4.7% above its 200-day moving average of $243.87.

Recent Earnings

Johnson & Johnson posted trailing-twelve-month revenue of $99,334,995,968 alongside earnings of $6.59 per share. The company reported a year-over-year revenue growth rate of 5.9% and a net profit margin of 16.2%. Its next earnings report is scheduled for January 26, 2027.

Dividend

Johnson & Johnson pays an annual dividend with a yield of 2.12%, supported by a payout ratio of 60.7%.

Insider Buying and Selling at Johnson & Johnson

Officer Elizabeth Forminard sold 15,918 shares on August 6, 2026, totaling $4,090,960. Chief Executive Officer Joaquin Boix Duato sold 123,291 shares on August 13, 2026, totaling $32,199,927. Officer Jennifer L Taubert sold 15,000 shares on August 17, 2026, at an average price of $263.36, totaling $3,950,400. Officer Timothy Schmid sold 33,597 shares on September 2, 2026, at an average price of $274.74, totaling $9,230,440.

Analysts Set New Price Targets

On October 7, 2026, Guggenheim reiterated its buy rating on Johnson & Johnson with a price target of $287.00. On October 14, 2026, Leerink Partners maintained an outperform rating, lowering its target from $276.00 to $272.00. On the same day, Wells Fargo maintained an overweight rating, adjusting its target down from $282.00 to $275.00. RBC Capital also maintained an outperform rating on October 14, 2026, moving its target from $290.00 to $280.00. Later, on October 15, 2026, Morgan Stanley maintained an overweight rating with a price target of $292.00, down from $294.00. The stock currently holds a consensus buy rating from analysts with a mean price target of $279.41 across 22 opinions.

About Johnson & Johnson

Johnson & Johnson operates as a healthcare products company focusing on research, development, and manufacturing across pharmaceuticals and medical technology. The firm organizes its business into two primary segments, Innovative Medicine and MedTech, serving patients and providers worldwide.

Bottom Line

Investors tracking Fort Washington Investment Advisors will need to check future SEC filings to see if the fund continues trimming its exposure to Johnson & Johnson. The next major company update will arrive with earnings on January 26, 2027.